Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Language
Affiliation country
Publication year range
1.
Biomed Pharmacother ; 132: 110889, 2020 Dec.
Article in English | MEDLINE | ID: mdl-33113429

ABSTRACT

The endocannabinoid system (ECS) is natural physiological system in the humans. The presence of the ECS system involves different roles in body. The endocannabinoid system involves regulation of most of the centers, which regulates the hunger and leads to changes in the weight. In the present article, we reviewed the role of natural cannabinoid compounds in metabolic disorders and related complications. We studied variety of a plant-derived cannabinoids in treating the metabolic syndrome including stoutness, fatty acid liver diseases, insulin obstruction, dementia, hypertension, lipid abnormalities, non-alcoholic steatohepatitis, endothelial damage, and polycystic ovarian syndrome and so on. The activation of cannabinoid receptors demonstrates a significant number of beneficial approaches concerning metabolic syndrome and reduces the pro-inflammatory cytokines on account of aggravation, decreased oxidative stress and uneasiness, diminishes liver fibrosis, with reduces adiponectin. Pre-clinical investigations of plant-derived cannabinoids resulted in promising outcomes. The different distinctive plant-derived cannabinoids were discovered like cannabidiol (CBD), cannabinol (CBN), cannabichromene (CBC), and cannabidiol (CBG). It has been observed that endogenous cannabinoids and plant-derived cannabinoids have an advantageous impact on limiting the metabolic disorder arising due to lifestyle changes.


Subject(s)
Cannabinoid Receptor Agonists/therapeutic use , Cannabinoid Receptor Antagonists/therapeutic use , Cannabinoids/therapeutic use , Endocannabinoids/metabolism , Metabolic Syndrome/drug therapy , Plant Extracts/therapeutic use , Receptors, Cannabinoid/drug effects , Animals , Cannabinoid Receptor Agonists/adverse effects , Cannabinoid Receptor Agonists/isolation & purification , Cannabinoid Receptor Antagonists/adverse effects , Cannabinoid Receptor Antagonists/isolation & purification , Cannabinoids/adverse effects , Cannabinoids/isolation & purification , Drug Partial Agonism , Humans , Metabolic Syndrome/metabolism , Plant Extracts/adverse effects , Plant Extracts/isolation & purification , Plants, Medicinal , Receptors, Cannabinoid/metabolism , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL